Unstable atherosclerotic plaque. Pathophysiology and therapeutic guidelines

Acta Cardiologica

Volumn 53, Issue 4, 1998, Pages 235-241

  Berkenboom, Guy ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Angiotensin II; Atherosclerosis; EDNO; Oxidized LDL; Plaque rupture; Superoxide onion

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN; ANTICOAGULANT AGENT; CALCIUM ANTAGONIST; CELL ADHESION MOLECULE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PROBUCOL; STATIN; TICLOPIDINE;

ACUTE DISEASE; ARTICLE; ATHEROSCLEROTIC PLAQUE; ENZYME ACTIVITY; HEART MUSCLE ISCHEMIA; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; THROMBOGENESIS;

CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLATELET AGGREGATION INHIBITORS;

EID: 0032422380     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Giroud D, Li JM, Urban P, Meiser B, Rutishauser W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992; 69: 729-732.
2. Moise A, Lesperance J, Theroux P, Taeymans Y, Goulet C, Bourassa MG. Clinical and angiographic predictors of new total coronary occlusion in coronary artery disease: analysis of 313 nonoperated patients. Am J Cardiol 1984; 54: 1176-1181.
3. Hackett D, Verwilghen J, Davies G, Maseri A. Coronary stenoses before and after myocardial infarction. Am J Cardiol 1989; 63: 1517-1518.
4. Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, Lesperance J. Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences. Circulation 1985; 72: Suppl V: V71-V78.
5. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthetize nitric oxide from L-arginine. Nature 1988; 333: 664-666.
6. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
7. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38: 87-104.
8. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22 (suppl 4): S1-S14.
9. Berkenboom G, Unger P, Fang Z-Y, Degré S, Fontaine J. Comparison of responses to acetylcholine and serotonin on isolated canine and human coronary arteries. Cardiovasc Res 1989; 23: 780-787.
10. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988; 77: 43-52.
11. Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995; 25: 155-161.
12. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1419-1424.
13. Borneldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R., Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signalling pathways that are distinct from those of proliferation. J Clin Invest 1994; 93: 1266-1274.
14. Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pcctoris and normal coronary angiograms. Circulation 1996; 94: 130-134.
15. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-456.
16. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-2551.
17. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
18. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-1374.
19. Chin JH, Azhar S, Hoffmann BB. Inactivation of endothelial-dcrived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18.
20. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low-density lipoproteins: a potential role in recruitment and retention of monocytes/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-2998.
21. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850.
22. Galis Z, Muszynski M, Sukhova G, Simon-Morrisey E, Unemori E, Lark M, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-189.
23. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
24. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilation in humans, in vivo. Circulation 1997; 96: 3042-3047.
25. Bhagat K, Moss R, Collier J, Vallance P. Endothelial stunning following a brief exposure to endotoxin - a mechanism to link infection and infarction. Cardiovasc Res 1996; 32: 822-829.
26. Siegfried MR, Ma XL, Lefer AM. Splanchnic vascular endothelial dysfunction in rat endotoxemia: role of superoxide radicals. Eur J Pharmacol 1992; 212: 171-176.
27. Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, Tsujimoto Y, Morimoto S, Ogihara T. Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 1996; 27 (part 2): 823-826.
28. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
29. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
30. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767.
31. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
32. van Leeuwen RTJ, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-368.
33. 2+ concentrations in essential hypertension. Hypertension 1993; 22: 853-862.
34. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.
35. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop PW, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333: 1301-1307.
36. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
37. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993; 91: 1453-1458.
38. Wiemer G, Linz W, Hatrik S, Schölkens BA, Malinski T. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension 1997; 30: 1183-1190.
39. Berkenboom G, Langer I, Carpentier Y, Grosfils K, Fontaine J. Ramipril prevents endothelial dysfunction induced by oxidized low density lipoproteins. A bradykinin-dependent mechanism. Hypertension 1997; 30: 371-376.
40. Mancini GBJ, Henry GC, Macaya C, O'Neil BJ, Pucillo AL, Carere RG, Waegovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258-265.
41. Pfeffer MA, Braunwald E, Moye L, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas G, Packer M, Rouleau J, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
42. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-691.
43. Böger RH, Bode-Böger SM, Mügge A, Kienke S, Brandes R, Dwenger A, Frölich JC. Supplementation of hypercholesterolemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 1995; 117: 273-284.
44. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-1550.
45. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93: 1107-1113.
46. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
47. Solzbach U, Hornig B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997; 96: 1513-1519.
48. Weber C, Erl W, Weber K, Weber PC. Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation 1996; 93: 1488-1492.
49. Williams RJ, Motteram JM, Sharp CH, Gallagher PJ. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992; 94: 153-159.
50. Keaney JF Jr, Xu A, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest 1995; 95: 2520-2529.
51. Keaney JF Jr, Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, Loscalzo J, Vita JA. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994; 93: 844-851.
52. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-786.
53. Haller H. Mechanisms of early atherogenesis: cellular effects of calcium-channelblockers. J Cardiovasc Pharmacol 1997; 30 (Suppl 3): S1-S8.
54. Lichtlen PR, Hugenholtz PG, Rafflenbeul W. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial of Antiatherosclerotic Therapy (INTACT). Lancet 1990; 335: 1109-1113.
55. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the second-ary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749-756.
56. Stein B, Fuster V. Clinical pharmacology of platelet inhibitors. In: Thrombosis in cardiovascular disorders. Fuster V, Verstraete M (Eds), W.B. Saunders, Philadelphia, 1992; 99-120.
57. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1338.
58. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet GLYCOPROTEIN IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
59. Théroux P, Ouimet H, McCans J, Latour J-G, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.
60. The RISC Group: Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-830.
61. Marenberg ME, Risch N, Berkman LF, Floderus B, de-Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-1046.
62. Brenn T. Genetic and environmental effects on coronary heart disease risk factors in Northern Norway: the cardiovascular disease study in Finnmark. Human Genet 1994; 58: 369-379.
63. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corval P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half of the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
64. Erikson P, Kallin B, van Thooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855.
65. A polymorphism of glycoprotein IIb/IIIa and the fibrinogen β448 polymorphism with myocardial infarction and extent of coronary disease. Circulation 1997; 96: 1424-1431.
66. Gerard RD, Chan L. Adenovirus-mediated gene transfer: Strategies and applications in lipoprotein research. Curr Opin lipidol 1996; 7: 105-111.
67. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-374.
68. Lewis BS, Flugelman MY, Weisz A, Keren-Tal I, Schaper W. Angiogenesis by gene therapy: a new horizon for myocardial revascularization. Cardiovasc Res 1997; 35: 490-497.